Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on February 13, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 13, 2026 Medrx Co.,Ltd. [4586.T] TOKYO, Feb 13 (Pulse News Wire) – Medrx CO.,LTD. (4586.T) announced changes to the expenditure schedules for funds raised through equity warrants issued in its 25th and 32nd tranches. For the 25th tranche, the company delayed the start of clinical Phase II trials for MRX-4TZT, a spastic paralysis treatment drug, to December 24, 2025. As a result, expenses originally planned for the fiscal year ending December 2025 will now